Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 3, 2004, Pages 294-298

  Gil Delgado, Marian A ^a   Bastian, Gerard ^b   Guinet, François ^c   Spano, Jean Phillippe ^a   Taillibert, Sophie ^a   Rocher, Marie Ange ^a   Castaing, Denis ^c   Adam, René ^c   Urien, Saik ^b   Bismuth, Henry ^c   Khayat, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Hôpital René Huguenin   (France)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

Advanced colorectal carcinoma; Irinotecan; Oxaliplatin; Pharmacokinetic; Phase I II

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER RESECTION; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SEPTIC SHOCK;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS;

EID: 2942586609     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.COC.0000071383.39986.A4     Document Type: Article

References (18)

1. De Gramont A, Louvet C, André T, et al. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherches sur les Cancers de l'Ovaire et Digestifs (GERCOD°. Eur J Cancer 1998;34:619-26.
2. Lokich J. Infusional 5-FU: historical evolution, rationale and clinical experience. Oncology 1998;12(suppl 7):19-22.
3. De Gramont A, Bosset JF, Milan C, et al. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-15.
4. Shimada Y, Yoshima M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer in chemotherapy-naive patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1993;11:909-13.
5. De Fomi M, Bugat R, Chabot CG, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in colorectal cancer. Cancer Res 1994;54:4347-53.
6. Rothemberg ML, Eckardt J, Kuhn JC, et al. Phase II study of irinotecan in patients with progressive or rapidly recurrent colorectal carcinoma. J Clin Oncol 1996;14:1128-35.
7. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998;9:105-8.
8. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (LOHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;1:95-8.
9. Gilles-Amar V, Garcia ML, Sebille A, et al. Evolution of severe sensory neuropathy with oxaliplatin, combined to the bimonthly 48h leucovorin (LV) and 5-fluorouracil (5-FU) regimens (FOLFOX) in metastatic colorectal cancer [Abstract 944]. Proc Am Soc Clin Oncol 1999;18:246a.
10. Wasserman E, Kalla S, Misset JL, et al. Oxaliplatin (LOHP) and irinotecan (CPT-11). J Clin Oncol 1999;9:2901-8.
11. Cvitkovic E, Bekradda M. Oxaliplatin. A new therapeutic option in colorectal cancer. Semin Oncol 1999;26:647-62.
12. Urien S. Micropharm-K, a microcomputer interactive program for the analysis and simulation of pharmacokinetic processes. Pharm Res 1995; 12:1225-30.
13. European Organisation of Research and Treatment of Cancer (EORTC). A practical guide to EORTC Studies. Brussels, Belgium: EORTC Data Cancer, 1996;126.
14. Bismuth H, Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 1998;25: 40-6.
15. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-9.
16. Khayat D, Gil-Delgado M, Antoine EC, et al. The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Oncology 2001;15:4.
17. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
18. André T, Louvet C, Maindrault-Goedel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pre-treated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:1343-7.